In PLA2R-associated PMN patients with nephrotic syndrome or renal dysfunction, the early administration of glucocorticoids combined with immunosuppressants can reduce proteinuria and thrombosis and delay the progression of chronic renal disease; however, the choice of the appropriate immunosuppressive agent in the clinic is still controversial. Here, PLA2R1 is linked to nephrotic syndrome.